The clinical application of Pt-based anticancer drugs has inspired the development of novel
chemotherapeutic metallodrugs with improved efficacies. Pt (IV) prodrugs are one of the …

Platinum-based drugs have maintained their preeminent position in cancer treatment
regimens even four decades after the approval of cisplatin. Although these agents have …

The concept of multi-action octahedral platinum (IV) complexes is based on the rational
derivatization of anticancer square-planar platinum (II) compounds (eg, cisplatin or …

Controlled photoreduction of Pt (IV) prodrugs is a challenging task due to the possibility of
targeted light-controlled activation of anticancer agents without affecting healthy tissues …

Cancer is a long-known incurable disease, and the medical use of cisplatin has been a
significant discovery. However, the side-effects of cisplatin necessitate the development of …

A platinum (IV) prodrug, cis, cis, trans-[Pt (NH3) 2Cl2 (biotin)(L)](1), derived from cisplatin,
where HL is the PEGylated red-light active boron-dipyrromethene (BODIPY) ligand, was …

Photoactivatable Pt (IV) anticancer prodrugs with the structure of [PtIV (N1)(N2)(L1)(L2)(A1)(
A2)], where N1 and N2 are non-leaving nitrogen donor ligands, L1 and L2 are leaving …

Anticancer photodynamic therapy (PDT) in recent years has gained attention among
therapists due to its low systemic toxicity and non-invasive nature. Today, one of the big …

Using the principle of “Magic Bullet”, a cisplatin-derived platinum (IV) prodrug
heterobimetallic Pt (IV)–Ru (II) complex, cis, cis, trans-[Pt (NH3) 2Cl2 {Ru (tpy–BODIPY)(tpy …

Platinum anticancer drugs have been explored and developed in recent years to reduce
systematic toxicities and resist drug resistance. Polysaccharides derived from nature have …